GAIA

GAIA is a pioneering company dedicated to the development of evidence-based digital therapeutics that enhance both mental and physical health for patients. With over 20 years of expertise, GAIA offers more than 70 clinically proven products, including their flagship program, deprexis®, designed to effectively treat depression. This innovative therapy has demonstrated significant efficacy in 13 randomized controlled trials and real-world clinical settings, achieving effect sizes comparable to traditional antidepressants.

The GAIA team comprises multidisciplinary experts, including physicians, psychotherapists, and regulatory affairs specialists, ensuring high-quality product development, launch, and maintenance across major markets. Their commitment to rigorous clinical testing underscores the importance of randomized controlled trials (RCTs) in validating the safety and effectiveness of their offerings.

By providing accessible and safe digital therapeutics, GAIA empowers healthcare professionals, payers, and patients alike to achieve optimal mental health outcomes comparable to that of established pharmaceutical treatments. For more information on GAIA's groundbreaking work in digital therapeutics, visit their website.